With respect to molecular docking studies, we used Bcl-2, DHFR, HMG-CoA reductase, and FASN as targets and the three terpenoids with the best cytotoxic and anti-lymphoma activity obtained in in vitro and in vivo studies as ligands (Table 4, Figure 4, Figure 5, Figure 6 and Figure 7). The gene discussed is BCL2; the disease is lymphoma.